Humacyte, Inc. today announced the successful completion of its business combination (the "Business Combination") with Alpha Healthcare Acquisition Corp.
Alpha Healthcare Acquisition Corp. (Nasdaq: AHAC) ("AHAC"), a special purpose acquisition company, today announced that it has filed a definitive proxy statement with the Securities and Exchange Commission ("SEC") and set a date of August 24, 2021.
Human tissue bioengineering biotech Humacyte has entered into a business combination agreement with special purpose acquisition company (SPAC) Alpha Healthcare Acquisition Corp (AHAC).